Abstract
Attention deficit hyperactivity disorder (ADHD) is a prevalent childhood psychiatric disorder, with a major genetic component. Here we present a GWAS meta-analysis of ADHD comprising 38,691 individuals with ADHD and 186,843 controls. We identified 27 genome-wide significant loci, which is more than twice the number previously reported. Fine-mapping risk loci highlighted 76 potential risk genes enriched in genes expressed in brain, particularly the frontal cortex, and in early brain development. Overall, ADHD was associated with several brain specific neuronal sub-types and especially midbrain dopaminergic neurons. In a subsample of 17,896 exome-sequenced individuals, we identified increased load of rare protein-truncating variants in cases for a set of risk genes enriched with likely causal common variants, suggesting implication of SORCS3 in ADHD by both common and rare variants. We found ADHD to be highly polygenic, with around seven thousand variants explaining 90% of the SNP heritability. Bivariate gaussian mixture modeling estimated that more than 90% of ADHD influencing variants are shared with other psychiatric disorders (autism, schizophrenia and depression) and phenotypes (e.g. educational attainment) when both concordant and discordant variants are considered. Additionally, we demonstrated that common variant ADHD risk was associated with impaired complex cognition such as verbal reasoning and a range of executive functions including attention.
Competing Interest Statement
B.M.N. currently serve as a member of the scientific advisory board at Deep Genomics and Neumora (previously RBNC) and consultant for Camp4 Therapeutics, Takeda Pharmaceutical, and Biogen.
Funding Statement
D.D. was supported by the Novo Nordisk Foundation (NNF20OC0065561), the Lundbeck Foundation (R344 2020 1060) the European Unions Horizon 2020 research and innovation programme under grant agreement No. 965381(TIMESPAN). Research reported in this publication was supported by the National Institute Of Mental Health of the National Institutes of Health under Award Number R01MH124851. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The work was also supported by the European College of Neuropsychopharmacology (ECNP) Network ADHD Across the Lifespan. B.F. was also supported by funding from the European Communitys Horizon 2020 Programme (H2020/2014 2020) under grant agreements No. 728018 (Eat2beNICE) and No. 847879 (PRIME). B.F. also received relevant funding from the Netherlands Organization for Scientific Research (NWO) for the Dutch National Science Agenda NeurolabNL project (grant 400 17 602). S.E.M. was funded by NHMRC grants APP1172917, APP1158125 and APP1103623. This work was supported by the Instituto de Salud Carlos III (PI19/01224, PI20/0004), by the Pla Estrategic de Recerca i Innovacio en Salut (PERIS), Generalitat de Catalunya (METAL Cat; SLT006/17/287) by the Agencia de Gestio dAjuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2017SGR1461), Ministry of Science, Innovation and Universities (IJC2018 035346 I to M.S.A); by the European Regional Development Fund (ERDF) and by la Marato de TV3 (092330/31) and the ECNP Network ADHD across the Lifespan (https://www.ecnp.eu/researchinnovation/ECNP networks/List ECNP Networks/). T.Z. is funded by NIH, Grant No. R37MH107649 07S1 and by Research Council of Norway, NRC, Grant No. 288083. This study was also supported by the National Institutes of Health (NIH), Bethesda, MD under award numbers T32MH087004 (to K.T.), K08MH122911 (to G.V.), R01MH125246 (to P.R.) and U01MH116442 (to P.R.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The iPSYCH samples was approved by the Danish Data Protection Agency and the Scientific Ethics Committee in Denmark. The deCODE samples was approved by the National Bioethics Committee of Iceland
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
